Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.38)
# 2,677
Out of 5,182 analysts
121
Total ratings
43.52%
Success rate
-0.06%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Maintains: Buy | $14 → $15 | $4.00 | +275.00% | 5 | Apr 20, 2026 | |
| DFTX Definium Therapeutics | Maintains: Buy | $25 → $38 | $22.40 | +69.64% | 1 | Apr 16, 2026 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.27 | +648.90% | 5 | Apr 14, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $164 → $200 | $135.06 | +48.08% | 18 | Apr 7, 2026 | |
| BIIB Biogen | Maintains: Buy | $230 → $245 | $189.13 | +29.54% | 23 | Apr 1, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $20 → $18 | $9.32 | +93.13% | 6 | Mar 26, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $36 → $60 | $32.96 | +82.04% | 6 | Mar 20, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $35 | $27.92 | +25.36% | 1 | Mar 19, 2026 | |
| CLNN Clene | Maintains: Buy | $48 | $6.58 | +629.48% | 7 | Mar 13, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $21.28 | +83.27% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $24 | $10.61 | +126.20% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $27 | $3.73 | +623.86% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.90 | +207.69% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.25 | +6,300.00% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.35 | +47.65% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.71 | +1,444.80% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.86 | - | 2 | Jan 31, 2017 |
AtaiBeckley
Apr 20, 2026
Maintains: Buy
Price Target: $14 → $15
Current: $4.00
Upside: +275.00%
Definium Therapeutics
Apr 16, 2026
Maintains: Buy
Price Target: $25 → $38
Current: $22.40
Upside: +69.64%
Annovis Bio
Apr 14, 2026
Maintains: Buy
Price Target: $17
Current: $2.27
Upside: +648.90%
Neurocrine Biosciences
Apr 7, 2026
Maintains: Buy
Price Target: $164 → $200
Current: $135.06
Upside: +48.08%
Biogen
Apr 1, 2026
Maintains: Buy
Price Target: $230 → $245
Current: $189.13
Upside: +29.54%
COMPASS Pathways
Mar 26, 2026
Maintains: Buy
Price Target: $20 → $18
Current: $9.32
Upside: +93.13%
Stoke Therapeutics
Mar 20, 2026
Maintains: Buy
Price Target: $36 → $60
Current: $32.96
Upside: +82.04%
MapLight Therapeutics
Mar 19, 2026
Initiates: Buy
Price Target: $35
Current: $27.92
Upside: +25.36%
Clene
Mar 13, 2026
Maintains: Buy
Price Target: $48
Current: $6.58
Upside: +629.48%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $21.28
Upside: +83.27%
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $10.61
Upside: +126.20%
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $3.73
Upside: +623.86%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.90
Upside: +207.69%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.25
Upside: +6,300.00%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.35
Upside: +47.65%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.71
Upside: +1,444.80%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $35.86
Upside: -